David Nierengarten
Stock Analyst at Wedbush
(4.36)
# 338
Out of 5,239 analysts
237
Total ratings
54.04%
Success rate
16.85%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Reiterates: Neutral | $12 | $13.97 | -14.10% | 12 | May 12, 2026 | |
| STTK Shattuck Labs | Maintains: Outperform | $8 → $11 | $6.48 | +69.70% | 3 | May 8, 2026 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $11 | $4.77 | +130.61% | 16 | May 5, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $3.87 | +184.24% | 8 | May 5, 2026 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $58 → $59 | $59.28 | -0.47% | 8 | Apr 29, 2026 | |
| NVCR NovoCure | Reiterates: Neutral | $18 | $18.10 | -0.53% | 10 | Apr 16, 2026 | |
| FENC Fennec Pharmaceuticals | Reiterates: Outperform | $13 | $6.99 | +85.98% | 4 | Apr 16, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $65 → $80 | $74.15 | +7.89% | 2 | Apr 14, 2026 | |
| TLX Telix Pharmaceuticals | Reiterates: Outperform | $22 | $10.57 | +108.09% | 5 | Apr 13, 2026 | |
| NUVL Nuvalent | Reiterates: Outperform | $125 | $102.82 | +21.57% | 7 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $8.67 | +96.08% | 11 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $58 | $48.68 | +19.16% | 8 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $21.85 | +37.30% | 4 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $33.78 | +62.82% | 5 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $1,000 | $799.19 | +25.13% | 25 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $1.15 | +334.78% | 5 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $95 | $81.90 | +16.00% | 4 | Mar 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $65 | $31.52 | +106.22% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $110 | $119.13 | -7.66% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $88 | $68.55 | +28.37% | 5 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $22.42 | +38.27% | 7 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $7.95 | +214.47% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $5 → $7 | $2.07 | +238.16% | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $12.33 | +110.87% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $16.33 | -51.01% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $40.31 | -50.38% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $60.40 | -33.77% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $63.80 | -37.30% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $10.64 | +69.17% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.29 | +264.74% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $8.94 | +571.14% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $26.84 | +179.43% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.49 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.21 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $9.47 | - | 3 | Nov 20, 2017 |
Intellia Therapeutics
May 12, 2026
Reiterates: Neutral
Price Target: $12
Current: $13.97
Upside: -14.10%
Shattuck Labs
May 8, 2026
Maintains: Outperform
Price Target: $8 → $11
Current: $6.48
Upside: +69.70%
Nuvation Bio
May 5, 2026
Reiterates: Outperform
Price Target: $11
Current: $4.77
Upside: +130.61%
Perspective Therapeutics
May 5, 2026
Reiterates: Outperform
Price Target: $11
Current: $3.87
Upside: +184.24%
Kiniksa Pharmaceuticals International,
Apr 29, 2026
Maintains: Outperform
Price Target: $58 → $59
Current: $59.28
Upside: -0.47%
NovoCure
Apr 16, 2026
Reiterates: Neutral
Price Target: $18
Current: $18.10
Upside: -0.53%
Fennec Pharmaceuticals
Apr 16, 2026
Reiterates: Outperform
Price Target: $13
Current: $6.99
Upside: +85.98%
Spyre Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $65 → $80
Current: $74.15
Upside: +7.89%
Telix Pharmaceuticals
Apr 13, 2026
Reiterates: Outperform
Price Target: $22
Current: $10.57
Upside: +108.09%
Nuvalent
Apr 8, 2026
Reiterates: Outperform
Price Target: $125
Current: $102.82
Upside: +21.57%
Apr 1, 2026
Maintains: Outperform
Price Target: $20 → $17
Current: $8.67
Upside: +96.08%
Apr 1, 2026
Maintains: Outperform
Price Target: $56 → $58
Current: $48.68
Upside: +19.16%
Mar 31, 2026
Reiterates: Outperform
Price Target: $30
Current: $21.85
Upside: +37.30%
Mar 17, 2026
Reiterates: Outperform
Price Target: $55
Current: $33.78
Upside: +62.82%
Mar 9, 2026
Reiterates: Outperform
Price Target: $1,000
Current: $799.19
Upside: +25.13%
Mar 5, 2026
Maintains: Outperform
Price Target: $4 → $5
Current: $1.15
Upside: +334.78%
Mar 3, 2026
Maintains: Outperform
Price Target: $90 → $95
Current: $81.90
Upside: +16.00%
Feb 25, 2026
Maintains: Outperform
Price Target: $57 → $65
Current: $31.52
Upside: +106.22%
Feb 24, 2026
Initiates: Underperform
Price Target: $110
Current: $119.13
Upside: -7.66%
Feb 17, 2026
Maintains: Outperform
Price Target: $110 → $88
Current: $68.55
Upside: +28.37%
Jan 15, 2026
Reiterates: Outperform
Price Target: $31
Current: $22.42
Upside: +38.27%
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $7.95
Upside: +214.47%
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $2.07
Upside: +238.16%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $12.33
Upside: +110.87%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $16.33
Upside: -51.01%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $40.31
Upside: -50.38%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $60.40
Upside: -33.77%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $63.80
Upside: -37.30%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $10.64
Upside: +69.17%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.29
Upside: +264.74%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $8.94
Upside: +571.14%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $26.84
Upside: +179.43%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.21
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $9.47
Upside: -